A61K 40/422
Ephrin receptors [eph]
Official title: {Ephrin Receptors [Eph]}
A61K40/422 (Ephrin receptors [eph]) appears on 31 US grants and 68 published applications in this corpus.
Search patents in A61K- Granted patents
- 31
- Published applications
- 68
- Assignees
- 35
- Inventors
- 88
- Latest grant
- 14 Jul 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2005 | 0 | 2 |
| 2006 | 0 | 1 |
| 2007 | 1 | 1 |
| 2008 | 0 | 1 |
| 2009 | 1 | 0 |
| 2010 | 0 | 2 |
| 2011 | 0 | 1 |
| 2012 | 1 | 2 |
| 2013 | 2 | 1 |
| 2014 | 3 | 4 |
| 2015 | 1 | 0 |
| 2016 | 2 | 3 |
| 2017 | 0 | 2 |
| 2018 | 2 | 2 |
| 2019 | 1 | 5 |
| 2020 | 1 | 2 |
| 2021 | 2 | 5 |
| 2022 | 1 | 6 |
| 2023 | 2 | 6 |
| 2024 | 4 | 10 |
| 2025 | 1 | 6 |
| 2026 | 6 | 6 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Method for producing cell population containing CAR-expressing immune cells14 Jul 2026US 12,679,902 B2BrightPath Biotherapeutics Co., Ltd.
- Chimeric antigen receptor gene-modified lymphocyte having cytocidal effect16 Jun 2026US 12,655,390 B2Kyoto Prefectural Public University Corporation
- Chimeric GMCSF-IL18 receptor2 Jun 2026US 12,643,936 B2St. Jude Children?S Research Hospital
- Methods of treating glioblastomas26 May 2026US 12,636,345 B2The Regents of the University of California
- Engineered dendritic cell and use thereof10 Mar 2026US 12,569,559 B1InmuCell Therapy (US) INC.
- Methods of treating glioblastomas9 Jul 2026US 2026/0191931 A1The Regents of the University of California
- Universal immune cells for cancer immunotherapy21 May 2026US 2026/0139064 A1Baylor College of Medicine
- Therapeutic effect enhancer for enhancing effect of car-t therapy5 Mar 2026US 2026/0060935 A1Kabushiki Kaisha Toshiba
- Method for proliferating car-t cells, and lipid particles and kit for use in the method5 Mar 2026US 2026/0062717 A1Kabushiki Kaisha Toshiba
- Targeting epha3 and uses thereof26 Feb 2026US 2026/0055195 A1The Council of the Queensland Institute of Medical Research
Most cited
By later US patents
- Peptide vaccines for cancers expressing tumor-associated antigens39US 9,284,349 B2Oncotherapy Science, Inc. · 2016
- Peptide analogs capable of enhancing stimulation of a glioma-specific CTL response18US 7,612,162 B2University of Pittsburgh—Of the Commonwealth System of Higher Education · 2009
- EphA2 T-cell epitopes and uses therefor17US 7,297,337 B2MedImmune, LLC · 2007
- EphA2 T-cell epitopes and uses therefor11US 8,114,407 B22012
- Peptide vaccines for cancers expressing tumor-associated antigens5US 8,623,829 B2Oncotherapy Science, Inc. · 2014